Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxcinod - Fera/Nicox

Drug Profile

Naproxcinod - Fera/Nicox

Alternative Names: AZD 3582; HCT 3012; Naproxen nitroxybutylester; Nitronaproxen; NO-naproxen

Latest Information Update: 04 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Class Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Osteoarthritis
  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 27 Sep 2018 Nicox and Fera Pharmaceuticals amend their licensing deal and plan to develop naproxcinod for an undisclosed rare disease indication
  • 10 Nov 2015 Naproxcinod licensed to Fera Pharmaceuticals in USA
  • 28 Aug 2015 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top